A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells.
Jacquy, C.; Soree, A.; Lambert, Frédéricet al.
2000 • In British Journal of Haematology, 110 (3), p. 631-7
[en] Autologous transplantation using peripheral blood stem cells (PBSCs) collected after chemotherapy, followed by growth factor administration (ASCT), is increasingly used in the treatment of non-Hodgkin's lymphoma (NHL). However, quantitative data regarding contaminating malignant cells in the harvests are still scarce. We prospectively investigated 37 diffuse large-cell lymphomas (DLCLs) in complete remission (CR) that were treated according to multicentric protocols at our centre. DNA was extracted from the diagnostic lymph node. The complementarity-determining region (CDR) III was sequenced and a patient-specific oligomer synthesized. Contamination was evaluated semiquantitatively by polymerase chain reaction (PCR) and was confirmed by a limiting dilution analysis. PBSCs collected at regeneration after administration of granulocyte colony-stimulating factor (G-CSF), steady-state bone marrow (BM) and peripheral blood samples at CR were compared. DNA was available in 37 patients, from which 22 rearrangements could be sequenced. Patients (n = 15) who had both the required follow-up samples and a suitable clonal marker were investigated. In two cases, the patient-specific PCR assay set up at diagnosis later gave false-negative results in samples in which clonal DNA was still detectable by other sets of primers. PBSC contamination was highly variable: 7 out of 15 patients showed a PBSC/BM ratio of NHL cells greater than 1 log, whereas 8 out of 15 patients showed no difference and could vary from one apheresis to another. Eight ASCTs were performed, five of which used highly contaminated PBSCs: four patients relapsed early, three with disseminated lymphoma. Thus, 50% of DLCLs in CR seem to mobilize significantly malignant cells at regeneration under G-CSF. Considering the higher numbers of cells reinfused, this translates into a much higher number of lymphoma cells reinfused when compared with autologous bone marrow transplantation (ABMT). However, their clonogenic potential remains unknown and, despite concerning observations in certain cases, it is still unclear whether this has an impact upon the outcome of ASCT.
Disciplines :
Hematology
Author, co-author :
Jacquy, C.
Soree, A.
Lambert, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells.
Andersen N.S., Donovan J.W., Borus J.S., Poor C.M., Neuberg D., Aster J.C., Nadler L.M., Freedman A.S., Gribben J.G. (1997) Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90:4212-4221.
Aubin J., Davi F., Nguyen-Salomon F., Leboeuf D., Debert C., Taher M., Valensi F., Canioni D., Brousse N., Varet B. (1995) Description of a novel FR1 IGH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 9:470-479.
Bosly A., Gisselbrecht C., Coiffier B. (1993) Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: The GELA experience. Nouvelle Revue Francaise d'Hematologie 35:21-23.
Corradini P., Astolfi M., Cherasco C., Ladetto M., Voena C., Caracciolo D., Pileri A., Tarella C. (1997) Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin lymphomas treated with high-dose chemotherapy and peripheral blood progenitor autografting. Blood 89:724-731.
Gianni A.M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine 336:1290-1297.
Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., Bosly A., Dupriez B., Nouvel C., Tilly H., Lederlin P., Biron P., Briere J., Gaulard P., Reyes F. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH 87-2. Journal of Clinical Oncology 15:1131-1137.
Haioun C., Lepage E., Gisselbrecht C., Coiffier B., Doyen C., Morel P., Attal M., Tilly H., Deconinck E., Gaulard P., Reyes F. (1998) High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. Annals of Oncology 9.
Hardingham J.E., Kotasek D., Sage R.E., Dobrovic A., Gooley T., Dale B.M. (1993) Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplantation 1:15-20.
Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K.C. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392.
Jacquy C., Delepaut B., Van Daele S., Vaerman J.L., Zenebergh A., Brichard B., Vermylen C., Cornu G., Martiat P. (1997) A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. British Journal of Haematology 98:140-146.
Jacquy C., Lambert F., Soree A., Van Daele S., Heusterspreute M., Bosly A., Ferrant A., Parma J., Bron D., Martiat P. (1999) Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: The case for purging?. Bone Marrow Transplantation 7:681-686.
Johnson P.W.M., Price C.G.A., Smith T., Cotter F.E., Meerabux J., Rohatiner A.Z.S., Young B.D., Lister T.A. (1994) Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. Journal of Clinical Oncology 12:798-805.
Landman-Parker J., Aubin J., Delabesse E., Tabone M.D., Adam M., Millien C., Leboeuf D., Buzyn-Veil A., Dollfus C., Leverger G., Macintyre E.A. (1996) Simplified strategies for minimal residual disease detection in B-cell precursor acute lymphoblastic leukaemia. British Journal of Haematology 95:281-290.
Lombardo J.F., Hwang T.S., Maiese R.L., Millson A., Segal G.H. (1994) Optimal primer selection for clonality assessment by polymerase chain reaction analysis. III. Intermediate and high-grade B-cell neoplasms. Human Pathology 27:373-380.
Majolino I., Pearce R., Taghipour G., Goldstone A.H. (1997) Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Journal of Clinical Oncology 15:509-517.
McCann J.C., Kanteti R., Shilepsky B., Miller K.B., Sweet M., Schenkein D.P. (1996) High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation 2:37-43.
Nizet Y., Van Daele S., Lewalle P., Vaerman J.L., Philippe M., Vermylen C., Cornu G., Ferrant A., Michaux J.L., Martiat P. (1993) Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IGH probes and the polymerase chain reaction. Blood 82:1618-1625.
Ouspenskaia M.V., Johnston D.A., Roberts W.M., Estrov Z., Zipf T.F. (1995) Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: A description of the method and the principles involved. Leukemia 9:321-328.
Philip T., Armitage J.O., Spitzer G., Chauvin F., Jagannath S., Cahn J.Y., Colombat P., Goldstone A.H., Gorin N.C., Flesh M. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine 316:1493-1498.
Schmitz N., Linch D.C., Dreger P., Goldstone A.H., Boogaerts M.A., Ferrant A., Demuynck H.M., Link H., Zander A., Barge A. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357.
Sharp J.G., Kessinger A., Mann S., Crouse D.A., Armitage J.O., Bierman P., Weisenburger D.D. (1996) Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. Journal of Clinical Oncology 14:214-219.
Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., Morley A.A. (1992) Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13:444-448.
Takvorian T., Canellos G.P., Ritz J., Freedman A.S., Anderson K.C., Mauch P., Tarbell N., Coral F., Daley H., Yeap B. (1987) Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with poor prognosis. New England Journal of Medicine 316:1499-1506.
Williams C.D., Goldstone A.H., Pearce R.M., Philip T., Hartmann O., Colombat P., Santini G., Foulard L., Gorin N.C. (1996) Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. Journal of Clinical Oncology 14:2454-2464.
Wu G.Q., Sharp J.G., Wu G., Vose J., Greiner T.C., Chan W.C. (1997) The detection of minimal lymphoma by molecular and combined culture-molecular methods. British Journal of Haematology 99:873-881.
Zwicky C.S., Maddocks A.B., Andersen N., Gribben J.G. (1996) Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 88:3314-3322.
